

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

RESULTS OF ANNUAL GENERAL MEETING HELD ON 15 MAY 2026

The Board of Directors (the “**Board**”) of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the “**Company**”) wishes to announce that at the Annual General Meeting (“**AGM**”) of the Company held on 15 May 2026, all resolutions relating to the matters set out in the Notice of AGM dated 30 April 2026 (superseding the Notice of AGM dated 16 April 2026) were passed.

Resolution(s) (poll voting)

The results of the poll on each of Resolutions 1 to 15 put to vote at the AGM are set out below. All Resolutions 1 to 15 were duly passed at the AGM.

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
1	To consider and approve the Chairman's Report for FY2025.	346326176	346253176	99.979	27900	0.008	45100	0.013
2	To consider and approve the Board of Directors' Report for FY2025.	346326176	346252776	99.979	27500	0.008	45900	0.013
3	To consider and approve the Financial Report and Audit Report for FY2025, which have been audited by CAC Certified Public	346326176	346252976	99.979	27500	0.008	45700	0.013

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	Accountants LLP (中审华会计师事务所) and Foo Kon Tan LLP, and reviewed by the Audit Committee of the Company.							
4	To consider and approve the profit distribution plan of the Company for FY2025.	346326176	346286376	99.989	26800	0.008	13000	0.004
5	To consider and approve the remuneration of S\$55,000 for Independent Director Mr. Yeo Guat Kwang (杨木光) for FY2025.	346326176	346131976	99.944	38700	0.011	155500	0.045
6	To consider and approve the remuneration of S\$55,000 for Independent Director Mr. Liew Yoke Pheng Joseph (刘育彬) for FY2025.	346326176	346126876	99.942	38700	0.011	160600	0.046
7	To consider and approve the remuneration of S\$55,000 for Independent Director Mr.	346326176	346123076	99.941	38700	0.011	164400	0.047

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	Zhong Ming (钟铭) for FY2025.							
8	To consider and approve the aggregate remuneration for the Directors of the Company for FY2025.	346326176	346186876	99.960	42900	0.012	96400	0.028
9	To consider and approve the proposed renewal of the shareholders' mandate for interested person transactions.	20470648	20375248	99.534	29000	0.142	66400	0.324
10	To consider and approve the proposed Company's "Shareholders' Return Plan for 2026 to 2028".	346326176	346252976	99.979	27200	0.008	46000	0.013
11	To consider and approve the proposed lines of credit granted to the Company up to an aggregate limit of RMB13,455 million.	346326176	346213776	99.968	32500	0.009	79900	0.023
12	To consider and	20470648	19888363	97.156	525385	2.567	56900	0.278

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	approve the proposed entry into the financial services agreement between the Company and Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) (“TPGF”) as an interested person transaction and all transactions arising therefrom.							
13	To consider and approve the proposed provision by the Company, in proportion to its equity interest in Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) (“Taiping Medicine”), of a guarantee of up to RMB1,408,875,000 in respect of credit facilities to be obtained by Taiping Medicine from third-party financial	20470648	20326648	99.297	65200	0.319	78800	0.385

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	institutions as an interested person transaction.							
14	To consider and approve the proposed provision by the Company, in proportion to its indirect equity interest in Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) (“ TJZX Medicine ”) (through Taiping Medicine), of a guarantee of up to RMB1,257,150,000 in respect of credit facilities to be obtained by TJZX Medicine from third-party financial institutions as an interested person transaction.	20470648	20310648	99.218	66100	0.323	93900	0.459
15	To consider and approve the proposed provision by the Company, in proportion to its indirect equity interest in TJZX	20470648	20314748	99.238	66000	0.322	89900	0.439

No.	Resolutions relating to:	Total number of shares represented by votes for and against the relevant resolution	FOR		AGAINST		FORFEITED	
			Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)	Number of shares	As a percentage of total number of votes for and against the resolution (%)
	Medicine (through Taiping Medicine), of a guarantee of up to RMB433,500,000 in respect of credit facilities to be obtained by TJZX Medicine from TPGF as an interested person transaction.							

Resolution(s) (cumulative voting)

The result of Resolution 16 put to vote by way of cumulative voting at the AGM is set out below. Resolution 16 was duly passed at the AGM, and Ms. Zhai Shuping (翟淑萍) (“**Ms. Zhai**”) was successfully appointed as an Independent Director of the Company with effect from the date of the AGM.

No.	Resolution(s) relating to:	Total number of shares represented by votes for and against the relevant resolution	Number of votes for the relevant resolution	As a percentage of total number of votes for and against the resolution (%)
To consider and approve the proposed appointment of one (1) Independent Director of the Company				
16	To consider and approve the proposed appointment of Ms. Zhai Shuping (翟淑萍) as an Independent Director of the Company.	346326176	343271973	99.118

Details of parties who are required to abstain from voting on any resolution

The following Director of the Company abstained from voting on Resolution 8 in relation to the aggregate remuneration for the Directors of the Company for FY2025:

Name	Number of shares held
Zhou Hong	23,800 Restricted A-shares

Tianjin Pharmaceutical Holdings Co., Ltd. (“**TPH**”) (being the controlling shareholder of the Company), which holds 325,855,528 A-shares in the Company, and Jinyao Global Pte. Ltd. (formerly known as Tianjin Pharmaceutical (Singapore) International Investment Pte. Ltd.) (being a wholly-owned subsidiary of TPH), which holds 5,347,200 S-shares in the Company, abstained from voting on Resolution 9 in relation to the proposed renewal of the shareholders’ mandate for interested person transactions, Resolution 12 in relation to the proposed entry into the financial services agreement between the Company and TPGF as an interested person transaction and all transactions arising therefrom, and Resolutions 13, 14 and 15 in relation to the proposed guarantees as interested person transactions. Further, Jinhushen Biological Medical Science and Technology Co., Ltd (津沪深生物医药科技有限公司) (being the controlling shareholder of TPH), which holds 4,497 A-shares in the Company, also abstained from voting on Resolutions 9, 12, 13, 14 and 15. In addition, TPH and its associates did not accept nominations as proxies or otherwise for voting on Resolutions 9, 12, 13, 14 and 15 at the AGM, unless they were given specific instructions by independent shareholder(s) as to how to vote.

Note of appreciation to the retiring Director

Mr. Liew Yoke Pheng Joseph (刘育彬) (“**Mr. Liew**”), an Independent and Non-Executive Director, retired as a Director of the Company at the conclusion of the AGM upon the expiry of his term of office. Mr. Liew was previously the Chairman of the Audit Committee and a member of the Remuneration Committee. The Board would like to express its appreciation to Mr. Liew for his invaluable contributions and insightful guidance to the Company during his tenure. Please also refer to the separate announcement made by the Company in respect of Mr. Liew’s retirement as a Director of the Company, as required under Rule 704(7) of the Listing Manual.

Appointment of Director to the Audit Committee

Following her appointment as an Independent Director of the Company, Ms. Zhai will be appointed as the Chairman of the Audit Committee in place of Mr. Liew. She will also serve as a member of the Remuneration Committee. Ms. Zhai is considered by the Board to be independent for the purposes of Rule 704(8) of the Listing Manual. Please also refer to the separate announcement made by the Company in respect of Ms. Zhai’s appointment as a Director of the Company, as required under Rule 704(7) of the Listing Manual.

Consequently, the composition of the Board and each of the Board Committees shall be as follows:

Board of Directors

Chairman	:	Ms. Wang Lei
Executive Directors	:	Mr. Guo Min Ms. Wang Lei Mr. Zhou Hong Mr. Shang Mingjie
Non-Executive and Non-Independent Directors	:	Mr. Xing Jianhua Ms. Mao Weiwen
Independent and Non-Executive Director	:	Mr. Yeo Guat Kwang (Lead Independent Director) Ms. Zhai Shuping Mr. Zhong Ming

Audit Committee

Chairman : Ms. Zhai Shuping

Members : Mr. Yeo Guat Kwang
Mr. Zhong Ming

Nomination Committee

Chairman : Mr. Zhong Ming

Members : Mr. Guo Min
Mr. Yeo Guat Kwang

Remuneration Committee

Chairman : Mr. Yeo Guat Kwang

Members : Ms. Mao Weiwen
Ms. Zhai Shuping

Strategy and Sustainability Committee

Chairman : Ms. Wang Lei

Members : Mr. Guo Min
Mr. Xing Jianhua

Scrutineer

Pursuant to Rule 704(16) of the Listing Manual, Drewcorp Services Pte. Ltd. acted as the Company's scrutineer for the AGM.

BY ORDER OF THE BOARD

Jiao Yan
Secretary to the Board of Directors
15 May 2026